Literature DB >> 10823139

Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analyses.

H C van Doorn1, C W Burger, P van der Valk, H M Bonfrèr.   

Abstract

AIM: To investigate the correlation between immunohistochemical and biochemical steroid receptor analyses by measurement of oestrogen, progesterone, and androgen receptor status in ovarian neoplasia.
METHODS: Tissue samples were obtained from 27 ovarian neoplasms, including two borderline tumours. Immunohistochemical staining of the tissue slides was scored semiquantitatively, incorporating the intensity and percentage of positive staining (histo-score). Tumours with a histo-score of 10 or more were considered steroid receptor positive. The epithelial and stromal fractions of the tumours were analysed separately. To study the uniformity of receptor expression throughout a tumour, up to four samples were analysed.
RESULTS: Immunohistochemical histo-scores of the oestrogen receptor in the epithelial fractions were significantly correlated with the biochemical oestrogen receptor values (r = 0.408). Androgen receptor status in the epithelial fraction was correlated with that in the stromal fraction (r = 0.741), while androgen receptor histo-scores in the epithelial fraction correlated with the biochemical assay values (r = 0.463). On biochemical analysis, 17 of the 27 ovarian tumours were oestrogen receptor positive and seven were progesterone receptor positive. On immunohistochemical analysis, eight tumours were oestrogen receptor positive and two were progesterone receptor positive. Biochemical analysis showed that 14 of the 26 tumours were slightly androgen receptor positive (10-50 fmol/mg protein), while all the others were negative. On immunohistochemical analysis, seven of the 26 tumours were androgen receptor positive. When two or more specimens from one tumour were analysed, marked differences in steroid status were found, especially in progesterone receptor and androgen receptor expression. Some parts of a tumour were steroid receptor positive, while other parts were negative owing to heterogeneity of expression.
CONCLUSIONS: Immunohistochemical and biochemical analysis of steroid receptors in ovarian tumours correlated weakly or not at all. Heterogeneity of expression within a tumour and the presence of progesterone and androgen receptors in the stromal fraction partly accounted for this observation. Biochemical and immunohistochemical androgen receptor status was much lower than in previous reports.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823139      PMCID: PMC1731160          DOI: 10.1136/jcp.53.3.201

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  22 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  The relationship of steroid receptor expression to nuclear DNA distribution and clinicopathological characteristics in epithelial ovarian tumors.

Authors:  M L Friedlander; M A Quinn; D Fortune; M S Foo; M Toppila; C N Hudson; P Russell
Journal:  Gynecol Oncol       Date:  1989-02       Impact factor: 5.482

3.  Quantification of oestrogen receptors in breast cancer: radiochemical assay on cytosols and cryostat sections compared with semiquantitative immunocytochemical analysis.

Authors:  H M Scheres; A F De Goeij; M J Rousch; G G Hondius; D D Willebrand; A H Gijzen; F T Bosman
Journal:  J Clin Pathol       Date:  1988-06       Impact factor: 3.411

4.  Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: Correlation between biochemical and immunohistochemical methods and survival.

Authors:  J T Chambers; M L Carcangiu; I M Voynick; P E Schwartz
Journal:  Am J Clin Pathol       Date:  1990-09       Impact factor: 2.493

5.  [Steroid hormone receptors in ovarian carcinomas and their clinical significance].

Authors:  H Geyer; G Teufel; G de Gregorio; A Pfleiderer
Journal:  Onkologie       Date:  1984-05

6.  Steroid receptor content in human ovarian tumors: survival of patients with ovarian carcinoma related to steroid receptor content.

Authors:  O E Iversen; E Skaarland; E Utaaker
Journal:  Gynecol Oncol       Date:  1986-01       Impact factor: 5.482

7.  Estrogen receptors in 699 primary breast cancers: a comparison of immunohistochemical and biochemical methods.

Authors:  A Molino; R Micciolo; M Turazza; F Bonetti; Q Piubello; A Corgnati; L Sperotto; G Martignoni; A Bonetti; R Nortilli
Journal:  Breast Cancer Res Treat       Date:  1995-06       Impact factor: 4.872

8.  Estradiol and progesterone receptors in normal ovary and ovarian tumors.

Authors:  M Lantta
Journal:  Acta Obstet Gynecol Scand       Date:  1984       Impact factor: 3.636

9.  Androgen receptor predominance in human ovarian carcinoma.

Authors:  R Kühnel; J de Graaff; B R Rao; J G Stolk
Journal:  J Steroid Biochem       Date:  1987-03       Impact factor: 4.292

10.  Standardization of steroid receptor assays in human breast cancer--IV. Long-term within- and between-laboratory variation of estrogen and progesterone receptor assays.

Authors:  A Koenders; S M Thorpe
Journal:  Eur J Cancer Clin Oncol       Date:  1986-08
View more
  8 in total

1.  Observer accuracy in estimating proportions in images: implications for the semiquantitative assessment of staining reactions and a proposal for a new system.

Authors:  S S Cross
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

Review 2.  Revisiting the role of antiandrogen strategies in ovarian cancer.

Authors:  Dionysis Papadatos-Pastos; Konstantin J Dedes; Johann S de Bono; Stanley B Kaye
Journal:  Oncologist       Date:  2011-09-23

3.  Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk.

Authors:  Kathryn L Terry; Immaculata De Vivo; Linda Titus-Ernstoff; Mei-Chiung Shih; Daniel W Cramer
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

4.  Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats.

Authors:  Allison C Sharrow; Brigitte M Ronnett; Christopher J Thoburn; James P Barber; Robert L Giuntoli; Deborah K Armstrong; Richard J Jones; Allan D Hess
Journal:  J Ovarian Res       Date:  2010-03-31       Impact factor: 4.234

5.  Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression.

Authors:  Miriam S Butler; Carmela Ricciardelli; Wayne D Tilley; Theresa E Hickey
Journal:  Horm Cancer       Date:  2013-02-27       Impact factor: 3.869

6.  The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.

Authors:  Angela George; Jennifer McLachlan; Nina Tunariu; Chiara Della Pepa; Cristina Migali; Martin Gore; Stan Kaye; Susana Banerjee
Journal:  BMC Cancer       Date:  2017-06-30       Impact factor: 4.430

Review 7.  The Role of Androgen Receptor Signaling in Ovarian Cancer.

Authors:  Taichi Mizushima; Hiroshi Miyamoto
Journal:  Cells       Date:  2019-02-19       Impact factor: 6.600

8.  Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037).

Authors:  Susana Banerjee; Holly Tovey; Rebecca Bowen; Elizabeth Folkerd; Lucy Kilburn; Jennifer McLachlan; Marcia Hall; Nina Tunariu; Ayoma Attygalle; Joao Paulo Da Silveira Nogueira Lima; Sophie Perry; Peter Chatfield; Margaret Hills; Stan Kaye; Gert Attard; Mitch Dowsett; Judith M Bliss
Journal:  Ther Adv Med Oncol       Date:  2020-12-29       Impact factor: 8.168

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.